Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing
American Economic Journal: Economic Policy · 01.11.2026 · 18 (4) · 245-272
DOI: 10.1257/pol.20240814 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Economic Journal: Economic Policy, erschienen am 01.11.2026. Verfasst von Christopher Hollrah. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
This paper measures how cost sharing impacts older low-income patients, exploiting a discontinuity in eligibility for a prescription drug subsidy for those who lose access to the Medicaid-linked program. Higher drug prices resulting from subsidy loss lead to a 40 percent reduction in prescription expenditures, driven by a 16 percent quantity reduction of prescriptions filled. Patients economize on purchases of higher-priced drugs, irrespective of their health benefits. For example, patients reduce insulin purchases by 35 percent. There is no evidence that cost sharing prompts switching from branded drugs to generics. This behavior suggests that cost sharing reduces prescription accessibility without enhancing cost-effectiveness. (JEL D24, I11, I18, I32, I38, L65)
Zitieren
APA
Hollrah, C. (2026). Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing. American Economic Journal: Economic Policy, 18(4), 245-272. https://doi.org/10.1257/pol.20240814
Vancouver
Hollrah C. Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing. American Economic Journal: Economic Policy. 2026;18(4):245-272. doi:10.1257/pol.20240814
BibTeX
@article{Hollrah2026,
author = {Hollrah, Christopher},
title = {Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing},
journal = {American Economic Journal: Economic Policy},
year = {2026},
volume = {18},
number = {4},
pages = {245--272},
doi = {10.1257/pol.20240814}
}
EUVIMED